Genentech to buy Regor's portfolio of next-generation CDK inhibitors to treat breast cancer: Cambridge, Massachusetts Tuesday, October 1, 2024, 10:00 Hrs [IST] Regor Pharmaceutica ...

Tim Pearson, one of the most Mayor Eric Adams’ influential advisers, has submitted a letter of resignation less than a week after the mayor was indicted on ...

The news reinforces CDK's reputation in the DMS business and, presumably, will help the company land more extensions and new ...

It hasn’t been the best of years for CDK Global, but it got some good news Monday. Sonic Automotive, one of the nation’s ...

The contract extension with Sonic is a win for market leader CDK, which faced challenges over the summer after two ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash payment ...

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to ...

Sino-American biotech Regor Pharmaceuticals has entered into a definitive purchase agreement whereby Swiss pharma major Roche ...

CDK, the leading automotive retail software provider, today announced the extension of its agreement with Sonic Automotive, ...

Roche is spending $850 million upfront to buy Regor Pharmaceuticals’ suite of next-generation CDK inhibitors as it doubles ...

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will ...